Welcome
Organising Committee
Acknowledgements
Four Seasons Hotel Floor Plan
Exhibition Floor Plan
Exhibitor Listing
Invited Speakers
International Speakers' Biographies
National Speakers' Biographies
Program at a Glance
Scientific Program
Poster Listing
1. SKIN TOXICITY OF TYROSINE KINASE INHIBITORS AND THE RELATIONSHIP TO EFFICACY
2. THE IBS AND ABS OF COLORECTAL CANCER
WHY WE NEED TO SELECT THE RIGHT PATIENTS FOR THE RIGHT DRUGS AND THE RIGHT DRUGS FOR THE RIGHT PATIENTS
UROTHELIAL CARCINOMA - CAN WE INDIVIDUALISE OUR APPROACH?
INTEGRATING TARGETED THERAPIES IN LUNG CANCER : TARGET PRACTICE OR HAVE WE FOUND THE FIVE HOLE?
TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
CANCER SURVIVORSHIP - AN OVERVIEW
MEASURING & MEETING UNMET NEEDS IN CANCER SURVIVORS
THE POTENTIAL ROLE OF PRIMARY CARE IN CANCER SURVIVORSHIP
THE POTENTIAL ROLE OF THE NURSE IN SHARED CARE FOR CANCER SURVIVORS
THE TENSION BETWEEN EVIDENCE-BASED MEDICINE AND PERSONALISED MEDICINE
THE TENSION BETWEEN EVIDENCE-BASED MEDICINE AND PERSONALISED MEDICINE
3. ZEN MOMENTS IN A CHALLENGING DISEASE : PERSONALISED MEDICAL ONCOLOGY IN TRANSITION
4. SEQUENCING OF THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC) : REAL CHANGE OR SIMPLY SHIFTING THE DECK CHAIRS
HEALTH REFORM AND CANCER : FIRST HAND EXPERIENCES FROM THE COMMISSION CHAIRPERSON
HEALTH REFORM AND CANCER : THE NSW STATE PERSPECTIVE
IMPLEMENTING CHEMOTHERAPY PRESCRIBING SOFTWARE : STEPS TOWARDS AN ELECTRONIC MEDICAL RECORD
DEVELOPMENT OF AN INTEGRATED MEDICAL ONCOLOGY PRACTICE SYSTEM
INFORMATION, EDUCATION AND QUALITY PRACTICE : JOINING THE DOTS
ADVOCACY 101
NATIONAL CANCER CONTROL POLICY DECISIONS 2004-2010 - AND THE ROLE OF ADVOCACY
PERSISTENCE, PERSISTENCE & REPETITION - THE IMPORTANCE OF ADVOCACY IN FORMING GOVERNMENT POLICY
WORKING EFFECTIVELY WITH GOVERNMENT
ADJUVANT LIPIODOL I-131 IN RESECTED HEPATOCELLULAR CARCINOMA : A RETROSPECTIVE REVIEW OF 22 PATIENTS
MORTALITY WITHIN 30 AND 60 DAYS OF RECEIVING SYSTEMIC ANTI-CANCER THERAPY AT A REGIONAL ONCOLOGY UNIT
CARDIAC DYSFUNCTION IN PATIENTS RECEIVING TRASTUZUMAB FOR EARLY STAGE BREAST CANCER IN THE SESIAHS
ANAL CANCER TREATMENT : CAN QUALITY ADVANCEMENTS BE MADE?
BLEOMYCIN DOSING FOR GERM CELL TUMOURS - ARE WE TOO CAUTIOUS?
COGNITIVE FUNCTION IN COLORECTAL CANCER (CRC) PATIENTS : INTERIM ANALYSIS OF A LONGITUDINAL PROSPECTIVE STUDY
MANAGEMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN VICTORIA IN 2003 : WHAT HAS CHANGED IN TEN YEARS?
AUSTRALIAN BREAST CANCER PATIENTS ENROLLED IN THE LAPATINIB EXPANDED ACCESS PROGRAM (LEAP)
HOW LONG HAVE I GOT? ESTIMATING TYPICAL, BEST CASE AND WORST CASE SCENARIOS FOR PATIENTS STARTING FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER : A SYSTEMATIC REVIEW OF RECENT RANDOMIZED TRIALS
SELF REPORTED COGNITIVE SYMPTOMS IN CANCER PATIENTS ATTENDING OUT-PATIENT MEDICAL ONCOLOGY CLINICS
INCIDENCE OF SKELETAL-RELATED EVENTS (SRES) IN BREAST CANCER (BC) PATIENTS WITH BONE METASTASES (BM) : DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA)
EFFICACY OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): ANALYSIS OF THE AUSTRALIAN SUBPOPULATION OF THE TRUST STUDY : 1
MANAGEMENT OF SMALL CELL LUNG CANCER (SCLC) IN VICTORIA IN 2003 : 2
TARGETED NANOPARTICLE FORMULATIONS FOR LUNG CANCER THERAPY : 3
PATIENTS' PREFERENCES FOR INTRAPERITONEAL CHEMOTHERAPY FOR ADVANCED OVARIAN AND RELATED CANCERS: WHAT MAKES IT WORTHWHILE? : 4
EFFICACY AND TOLERABILITY OF WEEKLY LOW DOSE CISPLATIN CONCURRENT WITH RADIOTHERAPY IN HEAD AND NECK CANCER PATIENTS: AN EXPERIENCE OF A REGIONAL CANCER CENTRE IN NORTH QUEENSLAND. : 5
GLUTATHIONE S-TRANSFERASE PI (GSTPI) FOR PREDICTION OF CHEMOTHERAPY RESPONSE AND SURVIVAL IN STAGE IV COLORECTAL CANCER : 6
DETECTING ACUTE NEUROTOXICITY DURING PLATINUM CHEMOTHERAPY BY NEUROPHYSIOLOGICAL ASSESSMENT OF MOTOR NERVE HYPEREXCITABILITY : 7
SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH ADVANCED SOLID TUMOURS OR MULTIPLE MYELOMA WITH BONE METASTASES (BM): RESULTS FROM A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY TRIAL COMPARING DENOSUMAB WITH ZOLEDRONIC ACID (ZA) : 8
BEVACIZUMAB AND IRINOTECAN FOR PROGRESSIVE GLIOBLASTOMA: OUR INSTITUTION'S EXPERIENCE : 9
MANAGEMENT OF THE VERY ELDERLY WITH LUNG CANCER: UNDERTREATMENT OR TOO UNWELL TO TREAT? : 10
HER2 TARGETED AGENTS IMPROVE OVERALL SURVIVAL IN HER2+ METASTATIC BREAST CANCER (MBC): A META-ANALYSIS : 11
POSTER WITHDRAWN : 12
TOXICITY PROFILE AND TOLERANCE OF CARBOPLATIN AUC2 USED IN CONCURRENT CHEMORADIATION OF HEAD AND NECK CANCER : 13
DELIVERY AND TOXICITY OF ADJUVANT FOLFOX AT THE ROYAL BRISBANE & WOMEN'S HOSPITAL : 14
PATIENTS TREATED WITH PLATINUM DOUBLET CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER HAVE INFERIOR OUTCOMES IF PREVIOUSLY TREATED WITH PLATINUM-BASED CHEMO-RADIATION : 15
TOXICITY AND PATIENT TOLERANCE OF OXALIPLATIN BASED TREATMENT FOR COLORECTAL CANCER (FOLFOX) - A RETROSPECTIVE AUDIT OF PATTERNS OF CARE IN TWO MAJOR CANCER CENTRES IN ADELAIDE
CART-WHEEL.ORG : ADVANCING THE STUDY OF RARE TUMOURS : 17
A RETROSPECTIVE SINGLE INSTITUTION COHORT STUDY OF METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH OXALIPLATIN-BASED CHEMOTHERAPY, WITH AN EXPLORATORY ANALYSIS OF CHANGING SERUM CARCINOEMBRYONIC ANTIGEN (CEA) LEVELS : 18
A RETROSPECTIVE CHART REVIEW OF CISPLATIN AND IRINOTECAN COMBINATION CHEMOTHERAPY IN RELAPSED SMALL CELL LUNG CANCER : 19
INITIAL TREATMENT OF METASTATIC COLORECTAL CANCER: USING PROSPECTIVE DATA TO UNDERSTAND AND IMPROVE ROUTINE CLINICAL PRACTICE : 20
LATE FATIGUE AFTER ADJUVANT THERAPY FOR BREAST CANCER IS LARGELY UNRELATED TO CANCER OR ITS TREATMENT: 5 YEAR FOLLOW UP OF A PROSPECTIVE COHORT STUDY * : 21